Viewing nowCombinationJanudam M Tablet 50/850 Milligram
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewong Bio Co., Ltd.

MFDS item code 202200206 · Approved 2022.01.12 · Insurance code 694004020
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to help control blood sugar levels in patients with type 2 diabetes. It can be administered in conjunction with diet and exercise therapy for more effective blood sugar management. It is used in cases where previous diabetes medications have not been used or where blood sugar control is difficult with monotherapy, and it can also be administered when monotherapy with metformin or sitagliptin is insufficient. Additionally, it can be used in combination with other medications such as metformin, sulfonylureas, thiazolidinediones, and insulin when sufficient blood sugar control is difficult. This drug is effective in improving blood sugar control in various combination therapies.
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medication should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medication is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Take This Medication). 2. Patients receiving metformin: - The recommended initial dose of this medication for patients who do not achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching to this medication from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When this medication is used with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medication because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medication).
This drug contains sitagliptin and metformin as active ingredients and is used for diabetes treatment. While taking this medication, a severe allergic reaction may occur, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or lips occur, discontinue use immediately and consult your doctor. Due to the risk of acute pancreatitis, if abdominal pain, vomiting, or persistent discomfort occurs after taking this medication, inform medical staff immediately. This medication should not be given to patients with severe renal impairment, acute heart failure, or serious infection conditions. Before and after tests using radiocontrast agents, this medication should be temporarily discontinued and can be resumed after kidney function has returned to normal. It is safer for pregnant women or those who may become pregnant, and breastfeeding women not to take this medication. While taking this medication, be cautious of hypoglycemic symptoms, especially when taken with other hypoglycemic agents, as the risk of hypoglycemia may increase. A rare but fatal side effect called lactic acidosis may occur, so if symptoms such as muscle pain, fatigue, difficulty breathing, or abdominal pain appear, inform medical staff immediately. Alcohol consumption may increase the risk of side effects from this medication, so it is advisable to avoid drinking alcohol while taking it. Elderly patients or those with reduced renal function should regularly undergo renal function tests, and dosage adjustments may be necessary. Additionally, this medication should be discontinued for a certain period before surgery, and can be resumed after confirming normal kidney function post-surgery. This drug may cause side effects such as gastrointestinal disturbances, headache, upper respiratory infections, etc., so consult medical staff if unusual symptoms persist. Lastly, it is important to regularly check health status with blood sugar and blood tests while taking this medication.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in an airtight container to prevent air and moisture from entering and is best kept at room temperature between 1 to 30 degrees Celsius. This helps maintain the effectiveness of the medication for a longer period.
Pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewong Bio Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.